| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-1654 |
| P698 | PubMed publication ID | 16467077 |
| P2093 | author name string | Joell J Gills | |
| Phillip A Dennis | |||
| Regan M Memmott | |||
| Courtney A Granville | |||
| P433 | issue | 3 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | disability | Q12131 |
| sirolimus | Q32089 | ||
| P304 | page(s) | 679-689 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway | |
| P478 | volume | 12 |
| Q33707181 | A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation |
| Q36482989 | A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases. |
| Q36755458 | Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors |
| Q40164038 | Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition |
| Q34872991 | Anaphylactic shock depends on PI3K and eNOS-derived NO. |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q24307014 | B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer |
| Q28397537 | Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities |
| Q37109227 | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. |
| Q45938898 | Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. |
| Q33354798 | Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer |
| Q28572913 | Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin |
| Q38112122 | Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer |
| Q42197476 | Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma |
| Q36651450 | Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart |
| Q36821373 | Emerging therapies for colorectal cancer |
| Q36097144 | Emerging therapies in pancreas cancer |
| Q35095146 | Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells |
| Q36784736 | Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vasorum endothelial cells |
| Q33694487 | Extracellular matrix molecules: potential targets in pharmacotherapy. |
| Q36901468 | Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth |
| Q37045209 | Genetic mutations involved in melanoma: a summary of our current understanding |
| Q34345248 | Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population |
| Q42758534 | Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma |
| Q35437204 | High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs |
| Q33266468 | High precision multi-genome scale reannotation of enzyme function by EFICAz |
| Q34995642 | Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules |
| Q36807494 | Inhibition of Akt pathways in the treatment of prostate cancer |
| Q45408203 | Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells |
| Q36568861 | Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. |
| Q35052439 | Integrating chemical and genetic silencing strategies to identify host kinase-phosphatase inhibitor networks that control bacterial infection |
| Q40043123 | Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. |
| Q93082677 | MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis |
| Q37211362 | Malignant melanoma in the 21st century: the emerging molecular landscape |
| Q30432032 | Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma |
| Q39132772 | Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. |
| Q36634023 | Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas |
| Q36086507 | PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma |
| Q28383083 | PI3K/PTEN signaling in angiogenesis and tumorigenesis |
| Q35606261 | Phosphatidylinositol-3-kinase as a therapeutic target in melanoma |
| Q36461618 | Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
| Q46956224 | Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells |
| Q39882765 | Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. |
| Q29614734 | Ras, PI(3)K and mTOR signalling controls tumour cell growth |
| Q33424649 | Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours |
| Q34261684 | Retracted: SPARC Overexpression Inhibits Cell Proliferation in Neuroblastoma and Is Partly Mediated by Tumor Suppressor Protein PTEN and AKT |
| Q36844334 | Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment |
| Q42868139 | Roles and controls of mTOR in the heart. Focus on "mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy". |
| Q39637442 | Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q37317000 | Targeting important pathways in head and neck cancer: from the bench to the clinic |
| Q36804407 | Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis |
| Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
| Q39951694 | The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition |
| Q37244719 | The biology and management of uveal melanoma |
| Q36561728 | The mTOR pathway in breast cancer |
| Q37894106 | The mTOR protein as a target in thyroid cancer. |
| Q37290512 | The molecular genetics of breast cancer and targeted therapy |
| Q46666883 | The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism |
| Q38983353 | The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro |
| Q37310991 | Translational up-regulation of Aurora-A in EGFR-overexpressed cancer |
| Q36791090 | YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression |
| Q37210960 | [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. |
| Q37317165 | mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials |
| Q43236080 | mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis |
Search more.